Waldenström's Macroglobulinemia — Structured Data
AI-optimized single page. All data for Waldenström's Macroglobulinemia in dense, structured format. Last updated: 2026-03-30.
View interactive disease hub · View all sources
Key Statistics
- Total reported cases
- Unknown
- Mean onset age
- 71 years
- Onset range
- 40–90 years
- Sex ratio (M:F)
- 2:1
- Diagnostic delay
- ~1 years
- Discovered
- 1944 (Jan Gösta Waldenström)
- Prevalence
- <1/1,000,000
- Classification
- hematologic, lymphoproliferative
- Pathophysiology
- well understood
- Treatment status
- effective options available
- Genetic basis
- well characterised
- Aliases
- WM, Lymphoplasmacytic Lymphoma with IgM, Waldenström macroglobulinemia, Waldenström's disease
Symptoms (10)
| Symptom | Frequency | Severity | Category | Description |
|---|---|---|---|---|
| Fatigue / normochromic normocytic anemia | 80% | cardinal | hematologic | Most common presenting symptom. Anemia results from bone marrow infiltration by lymphoplasmacytic cells, suppressing normal hematopoiesis. Hemoglobin typically 8-11 g/dL at presentation. |
| Monoclonal IgM paraproteinemia | 100% | cardinal | laboratory | Defining feature of WM. Serum IgM monoclonal protein produced by clonal lymphoplasmacytic cells. IgM concentration varies widely; levels correlate with hyperviscosity risk. |
| Bone marrow infiltration | 100% | cardinal | hematologic | Diagnostic requirement. Lymphoplasmacytic cells infiltrate bone marrow in diffuse, interstitial, or nodular pattern. Median marrow involvement ~60% at diagnosis. Causes cytopenias. |
| Peripheral neuropathy | 25% | major | neurologic | IgM-related demyelinating neuropathy, often with anti-MAG antibodies. Typically slowly progressive, distal, symmetrical, sensorimotor. May also present as ataxic neuropathy. |
| Hyperviscosity symptoms | 15% | cardinal | vascular | Caused by elevated pentameric IgM increasing blood viscosity. Manifests as oronasal bleeding, blurred vision (retinal venous engorgement), headache, dizziness, and neurologic dysfunction. Medical emergency requiring urgent plasmapheresis. |
| Lymphadenopathy | 20% | minor | lymphoid | Peripheral or central lymph node enlargement from lymphoplasmacytic infiltration. More common than in multiple myeloma. May be the presenting finding. |
| Hepatosplenomegaly | 20% | minor | organ_involvement | Hepatomegaly and/or splenomegaly due to lymphoplasmacytic infiltration. Splenomegaly may contribute to cytopenias. |
| Constitutional symptoms (B symptoms) | 25% | major | systemic | Fever, night sweats, and weight loss. Present in ~25% of patients at diagnosis. Weight loss is a distinguishing feature from marginal zone lymphoma in differential diagnosis. |
| Oronasal bleeding / mucosal hemorrhage | 10% | major | hematologic | Related to hyperviscosity and IgM interference with coagulation factors and platelet function. Epistaxis and gingival bleeding are classic presentations described by Waldenström in 1944. |
| Cold sensitivity / Raynaud phenomenon | 10% | minor | vascular | Related to cryoglobulinemia or cold agglutinin activity of the monoclonal IgM. Cold exposure precipitates symptoms. Cryoglobulinemia symptomatic in <5% of cases. |
Molecular Pathway (8 molecules)
| Molecule | Role | Expression change | Evidence level | Targeted by | Explanation |
|---|---|---|---|---|---|
| MYD88 | Central oncogenic driver (TLR/IL-1R adaptor) | L265P gain-of-function in >90% | established | Ibrutinib (indirect, via BTK) | MYD88 is the key adapter protein downstream of Toll-like receptors and IL-1 receptors. The L265P somatic mutation causes constitutive homodimerization and spontaneous Myddosome assembly, triggering NF-kB activation without ligand stimulation. This is the defining molecular event in WM, present in >90% of cases. |
| BTK (Bruton's Tyrosine Kinase) | Key signaling kinase downstream of MYD88 | Constitutively activated | established | Ibrutinib, Zanubrutinib, Pirtobrutinib | BTK is a non-receptor tyrosine kinase recruited to the Myddosome complex by mutated MYD88. It activates NF-kB pro-survival signaling independently of IRAK4/IRAK1. BTK also participates in B-cell receptor signaling. It is the direct target of ibrutinib and zanubrutinib, the most effective WM therapies. |
| NF-kB | Transcription factor driving B-cell survival | Constitutively activated | established | — | NF-kB is the convergent downstream target of both MYD88-IRAK and MYD88-BTK signaling arms. Constitutive NF-kB activation drives B-cell survival, proliferation, and IgM secretion. Loss of TNFAIP3 (A20) via 6q deletion in ~50% of patients further amplifies NF-kB activity. |
| IRAK4 | Myddosome kinase component | Constitutively activated | strong | — | IRAK4 is recruited to the Myddosome by mutated MYD88, along with IRAK1. Together they activate NF-kB through a pathway parallel to BTK. IRAK4 inhibitors are being explored as potential WM therapeutics. |
| CXCR4 | Chemokine receptor driving bone marrow homing | WHIM-like mutations in ~30-40% | established | — | CXCR4 is a chemokine receptor for CXCL12 (SDF-1). WHIM-like mutations (most commonly S338X) cause sustained receptor signaling and enhanced bone marrow homing. These mutations are associated with higher IgM, more hyperviscosity, and reduced response to BTK inhibitors. |
| HCK | SRC family kinase transactivated by mutated MYD88 | Upregulated | moderate | — | Mutated MYD88 triggers HCK gene expression through PAX5-mediated signaling. HCK is activated via IL-6/IL-6R/gp130/JAK2/STAT3 signaling and triggers BTK, SYK, and ERK1/2 cascades, providing an additional layer of pro-survival signaling. |
| IgM (Immunoglobulin M) | Pathogenic paraprotein causing end-organ damage | Elevated (monoclonal) | established | — | Monoclonal IgM is the effector molecule responsible for most WM complications. Its large pentameric structure causes hyperviscosity. Anti-MAG IgM causes neuropathy. IgM can also form cryoglobulins, cold agglutinins, or deposit as amyloid. IgM level is a treatment response marker. |
| TNFAIP3 (A20) | NF-kB negative regulator (tumour suppressor) | Deleted in ~50% (6q deletion) | strong | — | TNFAIP3 encodes A20, a key negative regulator of NF-kB signaling. Loss through chromosome 6q21-23 deletion occurs in ~50% of WM patients, removing the braking mechanism on NF-kB and synergising with MYD88 L265P to drive constitutive pathway activation. |
Genetic Findings (4)
| Gene | Variant | Type | Frequency in disease | Significance | Also found in |
|---|---|---|---|---|---|
| MYD88 | L265P (somatic) | somatic | >90% (up to 100% by AS-PCR) | Defining molecular hallmark of WM. Gain-of-function mutation causing constitutive Myddosome assembly, BTK activation, and NF-kB-driven B-cell survival. Discovered by Treon et al. 2012 via whole-genome sequencing. | Schnitzler syndrome (~30%); IgM-MGUS (~47%); DLBCL (ABC subtype) (~29%); Splenic marginal zone lymphoma (~6%) |
| CXCR4 | WHIM-like mutations (most commonly S338X) | somatic | ~30-40% | Second most common somatic event in WM. Over 40 different mutations described, both nonsense and frameshift. Mutations cause sustained CXCR4 signaling and enhanced bone marrow homing via CXCL12. | WHIM syndrome (~100% (germline)) |
| 6q21-23 (TNFAIP3, PRDM1) | Chromosomal deletion | somatic | ~50% | Large chromosomal deletion affecting multiple tumour suppressors. TNFAIP3 (A20) loss removes NF-kB negative regulation. PRDM1 loss disrupts B-cell to plasma cell differentiation. Additional deleted genes include BCLAF1, FOXO3, IBTK, and HIVEP2. | DLBCL (variable); CLL (variable) |
| Chromosomes 1q, 4q (susceptibility loci) | Germline susceptibility loci | germline | ~20% familial | ~20% of WM patients have a first-degree relative with a B-cell disorder. Genome-wide linkage analysis of high-risk families identified susceptibility loci on 1q and 4q (OMIM: 610430). Suggests dominant or co-dominant gene effects. | IgM-MGUS (elevated in first-degree relatives); Non-Hodgkin lymphoma (elevated in first-degree relatives) |
Treatment Evidence Matrix (9 treatments)
| Drug | Mechanism | Route | Response rate | Onset | IgM effect | Line | Explanation |
|---|---|---|---|---|---|---|---|
| Zanubrutinib | Second-generation selective BTK inhibitor | Oral 160mg BID or 320mg daily | ~95% ORR; 36% VGPR+CR | Weeks | Significant reduction | 1st | Next-generation BTK inhibitor with greater selectivity for BTK. The ASPEN phase III trial demonstrated comparable efficacy to ibrutinib with significantly improved safety: less atrial fibrillation (7.9% vs 23.5%), less hypertension, less diarrhea. Currently recommended as preferred first-line BTK inhibitor by Mayo Clinic guidelines. |
| Ibrutinib | First-generation BTK inhibitor | Oral 420mg daily | 90% ORR; 73% MRR (previously treated) | Weeks (median 4 weeks to minor response) | Significant reduction | 1st | First BTK inhibitor approved for WM. Directly targets MYD88-BTK-NF-kB axis. Response depends on genotype: MYD88mut/CXCR4wt patients achieve 100% ORR, while CXCR4-mutated and MYD88-WT patients have lower responses. Notable side effects include atrial fibrillation, hypertension, and bleeding. Also uniquely relevant in Schnitzler syndrome where it targets both inflammation and IgM. |
| Bendamustine + Rituximab (BR) | Alkylating agent + anti-CD20 monoclonal antibody | IV (bendamustine 90mg/m2 D1-2 + rituximab 375mg/m2 D1, q28d x6) | 91% (PR or better, frontline); 74% (relapsed) | Months | Major reduction | 1st | Highly effective chemoimmunotherapy regimen. Preferred when time-limited therapy is desired (typically 6 cycles). Major multicenter study of 250 patients confirmed high response rates. Limited by hematotoxicity and prolonged immunosuppression. Preferred Mayo Clinic first-line alongside zanubrutinib. |
| Rituximab | Anti-CD20 monoclonal antibody | IV 375mg/m2 weekly x4 or extended schedule | ~25-40% (monotherapy); higher in combinations | Months | Moderate reduction (caution: IgM flare in 40-50%) | 1st | Foundation of most WM combination regimens. Targets CD20+ lymphoplasmacytic cells. Important caveat: can cause transient IgM flare (increase) in 40-50% of patients in first weeks, potentially worsening hyperviscosity. Should be avoided as initial therapy in patients with high IgM or hyperviscosity symptoms. |
| Bortezomib (BDR regimen) | Proteasome inhibitor (with dexamethasone + rituximab) | SC 1.3mg/m2 (weekly) + dexamethasone + rituximab | ~80-85% (frontline BDR) | Weeks-months | Significant reduction | 1st | Proteasome inhibitor active against plasma cell component of WM. Used in BDR (bortezomib-dexamethasone-rituximab) combination. Effective in both frontline and relapsed settings. Risk of peripheral neuropathy limits use, especially in patients with pre-existing IgM neuropathy. Subcutaneous route reduces neuropathy risk. |
| Ibrutinib + Rituximab | BTK inhibitor + anti-CD20 antibody combination | Oral ibrutinib 420mg daily + IV rituximab | 82% 30-month PFS (vs 28% rituximab alone) | Weeks | Major reduction | 1st | The iNNOVATE phase III RCT demonstrated dramatic superiority of ibrutinib-rituximab over placebo-rituximab (HR 0.20, P<0.001). At 50-month follow-up, median PFS not reached. Benefits maintained regardless of MYD88 or CXCR4 status. Allows rituximab discontinuation after defined course while continuing ibrutinib. |
| Venetoclax | BCL2 inhibitor | Oral (dose escalation to 400mg daily) | ~70% MRR (relapsed/refractory) | Weeks-months | Significant reduction | 2nd | BCL2 inhibitor with activity in relapsed/refractory WM, including after BTK inhibitor failure. Being studied in combination with ibrutinib (fixed-duration) and pirtobrutinib. TP53 mutations may predict inferior outcomes. Requires dose escalation due to tumour lysis syndrome risk. |
| Pirtobrutinib | Non-covalent (reversible) BTK inhibitor | Oral 200mg daily | ~68% ORR (after covalent BTKi); 56% VGPR with venetoclax combo | Weeks | Reduction | 2nd | Non-covalent BTK inhibitor that retains activity after covalent BTK inhibitor resistance or intolerance. Being studied in combination with venetoclax (pirtobrutinib + venetoclax: 100% ORR, 56% VGPR in interim analysis). May overcome acquired BTK C481S resistance mutations. |
| Plasmapheresis | Physical removal of IgM from circulation | IV (therapeutic plasma exchange) | Immediate symptomatic relief | Hours | Acute reduction (temporary) | Adjunct | Emergency treatment for symptomatic hyperviscosity syndrome. Rapidly reduces IgM and serum viscosity. Effect is temporary; definitive therapy must follow. Also used before rituximab in patients with high IgM to prevent IgM flare. Essential component of acute WM management. |
Diagnostic Criteria
Owen et al. 2003 Consensus Criteria (2nd International Workshop on WM) (2003)
Sensitivity: ~95% · Specificity: ~90%
Major criteria (all required)
- IgM monoclonal gammopathy of any concentration
- Bone marrow infiltration by lymphoplasmacytic lymphoma (small lymphocytes with plasmacytoid/plasma cell differentiation, typically intertrabecular)
- Immunophenotype consistent with WM: surface IgM+, CD19+, CD20+, CD22+, CD25+, CD27+, FMC7+; typically CD5-/+, CD10-, CD23-
Minor criteria (0+ required)
All three major criteria required. Excludes other lymphoproliferative disorders that can secrete IgM (marginal zone lymphoma, mantle cell lymphoma, CLL). CD5 can be weakly positive in a minority of cases. CD23 typically negative but weak expression possible. Bone marrow biopsy with immunohistochemistry and flow cytometry is essential.
Updated IWWM Criteria with Molecular Testing (2023)
Sensitivity: ~98% · Specificity: ~95%
Major criteria (all required)
- IgM monoclonal gammopathy (any concentration)
- Bone marrow infiltration by lymphoplasmacytic lymphoma
- Immunophenotype: sIgM+, CD19+, CD20+, CD22+; CD5-, CD10-, CD23- (typical pattern)
- MYD88 L265P mutation testing recommended (positive in >90% of WM; aids distinction from other IgM-secreting lymphomas)
Minor criteria (0+ required)
- CXCR4 mutation testing (present in ~30-40%; informs prognosis and BTK inhibitor response)
- Cytogenetics/FISH for del(6q), trisomy 4, del(13q)
European Consortium for WM (ECWM) 2023 update builds on the 2003 Owen criteria by incorporating mandatory MYD88 mutation testing. MYD88 L265P supports the diagnosis; its absence (MYD88 wild-type, ~5-10%) should prompt consideration of marginal zone lymphoma or other IgM-secreting lymphomas. CXCR4 testing recommended for treatment planning. Flow cytometry panel should include CD19, CD20, CD5, CD10, CD23, CD25, CD27, CD38, CD138. Asymptomatic (smoldering) WM meets diagnostic criteria but does not require treatment.
Differential Diagnoses (7)
| Condition | Key distinction | Shared features |
|---|---|---|
| IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) | No bone marrow infiltration by lymphoplasmacytic lymphoma. IgM <3 g/dL. No symptoms of WM (no hyperviscosity, anemia, or constitutional symptoms). MYD88 L265P present in ~50% of IgM-MGUS. Progresses to WM at ~1.5% per year. | IgM monoclonal gammopathy, MYD88 L265P (in ~50%), Older age at detection |
| Schnitzler Syndrome | Chronic urticarial rash is the hallmark (absent in WM). IgM levels typically lower. Autoinflammatory mechanism (IL-1-driven). Bone marrow shows no lymphoplasmacytic infiltration. Responds to IL-1 blockade (anakinra). 15-20% may eventually progress to WM. | Monoclonal IgM, MYD88 L265P (in ~30% of Schnitzler), Possible shared pathogenesis via NF-κB |
| Marginal Zone Lymphoma (MZL) | Different immunophenotype: CD5-, CD10-, CD23-, but also CD25- and CD27- (unlike WM). MYD88 L265P rare (<10%) in MZL. Can secrete IgM but morphology differs. Splenic MZL has characteristic villous lymphocytes. | Indolent B-cell lymphoma, Can produce IgM monoclonal protein, Bone marrow involvement possible |
| Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) | CLL/SLL is CD5+ (WM is typically CD5-). CD23+ in CLL (CD23- in WM). Peripheral blood lymphocytosis is characteristic. Rarely secretes IgM. Different molecular landscape (del(13q), trisomy 12, del(11q), del(17p)). | Indolent B-cell malignancy, Bone marrow involvement, Elderly population |
| Multiple Myeloma | Predominantly IgG or IgA paraprotein (IgM myeloma is rare, <1%). Osteolytic bone lesions (WM has no lytic lesions). Hypercalcemia. CD138+/CD38+ plasma cell phenotype. Renal impairment from light chains. No MYD88 L265P. | Monoclonal gammopathy, Bone marrow infiltration, Anemia |
| AL Amyloidosis | Organ damage from amyloid fibril deposition (heart, kidney, liver, nerves). Diagnosed by Congo red staining of tissue biopsy with apple-green birefringence. Can coexist with WM (IgM-associated AL amyloidosis). Not a lymphoma per se but a complication of the underlying clone. | Monoclonal immunoglobulin, Peripheral neuropathy possible, Bone marrow clonal B-cells/plasma cells |
| Primary Cold Agglutinin Disease (CAD) | Autoimmune hemolytic anemia driven by cold-reactive IgM autoantibodies against red cell antigens. Bone marrow shows clonal B-cell population but not classical LPL morphology. MYD88 L265P is absent in most CAD (present in <5%). Complement-mediated hemolysis is the dominant feature. | IgM monoclonal protein, Clonal B-cell disorder, Older adults |
Hypotheses (5)
| Hypothesis | Domain | Status | Evidence score | Studies | Evidence for | Evidence against |
|---|---|---|---|---|---|---|
| MYD88 L265P is the founding mutation driving constitutive NF-κB and BTK signaling in WM | pathogenesis | leading | 90/100 | 85 |
|
|
| CXCR4 WHIM-like mutations act as secondary drivers affecting bone marrow homing and drug resistance | pathogenesis | leading | 78/100 | 40 |
|
|
| A two-hit model where MYD88 L265P provides the founding event and secondary mutations (CXCR4, ARID1A, TP53) shape disease phenotype | pathogenesis | leading | 75/100 | 30 |
|
|
| The WM clone originates from a post-germinal center, IgM-committed B cell that has undergone somatic hypermutation but not class-switch recombination | cell_of_origin | leading | 70/100 | 15 |
|
|
| The bone marrow microenvironment provides critical survival signals sustaining the WM clone | pathogenesis | competing | 55/100 | 20 |
|
|
Open Questions (5)
- Why does MYD88 L265P specifically cause WM rather than other B-cell lymphomas?
MYD88 L265P is found in >90% of WM but also occurs in other lymphomas (ABC-DLBCL, primary CNS lymphoma) at lower frequencies. The factors that determine WM-specific phenotype vs. other lymphoma types remain unknown. Cell of origin and cooperating mutations likely play a role. - What is the precise role of CXCR4 mutations in treatment resistance and can they be therapeutically targeted?
CXCR4 WHIM-like mutations are present in ~30-40% of WM patients and are associated with inferior BTK inhibitor response. Both nonsense and frameshift subtypes exist with different clinical impacts. CXCR4 antagonists (mavorixafor) are being explored but clinical data is limited. - What is the optimal sequencing and combination of BTK inhibitors and other agents?
Covalent BTK inhibitors (ibrutinib, zanubrutinib) are highly effective first-line. Non-covalent BTK inhibitors (pirtobrutinib) show activity after covalent BTK inhibitor failure. Venetoclax combinations and fixed-duration strategies are under investigation. No consensus on optimal sequencing. - Can WM be cured, and what would a curative strategy look like?
WM is considered incurable with current therapies. Complete responses are rare even with the most effective regimens. BTK inhibitors require indefinite treatment. Fixed-duration combinations (ibrutinib + venetoclax) aim for deep responses but long-term cure is unproven. Allogeneic stem cell transplant can be curative but carries prohibitive toxicity for an indolent disease. - Why does Schnitzler syndrome sometimes progress to WM, and can progression be predicted or prevented?
Approximately 15-20% of Schnitzler syndrome patients develop WM or other lymphoproliferative disorders over 10+ years. Both diseases share MYD88 L265P in a subset of patients. Whether IL-1 blockade in Schnitzler prevents lymphoproliferative transformation is unknown.
Complications (7)
| Complication | Risk | Timeframe | Description | Monitoring |
|---|---|---|---|---|
| Hyperviscosity syndrome | 10-30% | At diagnosis or during disease course; more common with IgM >3 g/dL | The large pentameric IgM molecule increases serum viscosity. Symptomatic hyperviscosity causes blurred vision, headache, epistaxis, gingival bleeding, and can progress to retinal hemorrhages, stroke, or heart failure. Funduscopic exam shows characteristic 'sausaging' of retinal veins. IgM levels <3 g/dL rarely cause symptomatic hyperviscosity. | Serum viscosity measurement with IgM monitoring. Funduscopic examination at baseline and with rising IgM. Urgent plasmapheresis for symptomatic hyperviscosity. |
| IgM-related peripheral neuropathy | 20-25% | Can present at diagnosis or develop during disease course | Demyelinating sensorimotor neuropathy is the most common pattern, frequently caused by IgM antibodies targeting myelin-associated glycoprotein (anti-MAG neuropathy). Presents with distal symmetric sensory loss, gait ataxia, and tremor. Can be severely disabling. Other patterns include CIDP-like neuropathy and sensory neuropathy. | Nerve conduction studies at baseline. Anti-MAG antibody testing. Neurological assessment for sensory and motor changes. Rituximab-based therapy is the primary treatment for anti-MAG neuropathy. |
| Cryoglobulinemia | 5-20% | Variable; can present at any point | IgM can form cryoglobulins (type I or mixed type II) that precipitate at low temperatures, causing vasculitis, Raynaud phenomenon, purpura, skin ulceration, arthralgia, and glomerulonephritis. Type I cryoglobulinemia (monoclonal IgM alone) is more common in WM than mixed cryoglobulinemia. | Serum cryoglobulin testing (proper warm handling of specimen essential). Monitor for purpura, Raynaud symptoms, renal function. Avoid cold exposure. |
| Cold agglutinin disease | 5-10% | Can present at diagnosis or later | IgM cold agglutinins bind red blood cells at low temperatures, activating complement and causing chronic hemolytic anemia. Symptoms include fatigue, jaundice, and acrocyanosis (blue discoloration of extremities in cold). Direct antiglobulin test (DAT) is positive for C3d. | Complete blood count, reticulocyte count, LDH, haptoglobin, DAT. Cold agglutinin titer. Avoid cold exposure. Complement inhibitors (sutimlimab) now available for CAD. |
| AL amyloidosis | ~5% | Usually develops years into disease course | IgM light chains (typically lambda) misfold into amyloid fibrils that deposit in organs, most commonly heart, kidneys, liver, and peripheral nerves. Cardiac involvement causes restrictive cardiomyopathy; renal involvement causes nephrotic syndrome. IgM-associated AL amyloidosis carries a poor prognosis if untreated. | Serum free light chains, NT-proBNP, troponin, proteinuria. Tissue biopsy (fat pad aspirate or organ biopsy) with Congo red staining if AL amyloidosis suspected. Echocardiography for cardiac involvement. |
| Bing-Neel syndrome (CNS involvement) | <5% | Rare; can occur at any point including as initial presentation | Direct infiltration of the central nervous system by lymphoplasmacytic lymphoma cells. Presents with headache, confusion, ataxia, cranial nerve palsies, or seizures. MRI shows leptomeningeal enhancement or parenchymal lesions. CSF cytology and flow cytometry confirm diagnosis. MYD88 L265P testing of CSF can aid diagnosis. | MRI brain/spine with contrast if neurological symptoms develop. Lumbar puncture with cytology, flow cytometry, and MYD88 mutation testing. Ibrutinib achieves good CNS penetration and is often used for treatment. |
| Transformation to diffuse large B-cell lymphoma (DLBCL) | 2-10% over disease course | Usually years to decades after WM diagnosis | Histological transformation to aggressive DLBCL (Richter-like transformation). Presents with rapidly enlarging lymphadenopathy, rising LDH, B symptoms, and extranodal disease. Associated with TP53 mutations and CDKN2A deletions. Prognosis is poor with median survival of 2-3 years after transformation. R-CHOP-based chemotherapy is standard treatment. | PET-CT if transformation suspected (rapidly growing nodes, elevated LDH). Excisional lymph node biopsy for histological confirmation. Annual LDH monitoring. |
Sources (34)
| Ref | Authors | Title | Journal | Year | Category | Type | Grade | Link |
|---|---|---|---|---|---|---|---|---|
| F2 | Gertz MA | WM: 2025 update on diagnosis, risk stratification, and management | Am J Hematol | 2025 | reviews | narrative review | B | DOI |
| E8 | Castillo JJ, et al. | Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive WM | Blood | 2024 | treatment | cohort | B | DOI |
| F3 | Bibas M, et al. | WM: State-of-the-Art Review Part 1 - Epidemiology, Pathogenesis, Clinical | Mediterr J Hematol Infect Dis | 2024 | reviews | narrative review | B | DOI |
| F4 | Treon SP, et al. | How I use genomics and BTK inhibitors in the treatment of WM | Blood | 2024 | reviews | expert opinion | B | DOI |
| G1 | Patel N, et al. | Pathophysiology and treatments of complications of WM | Clin Hematol Int | 2024 | clinical | narrative review | B | DOI |
| D1 | Dogliotti I, et al. | Diagnostics in WM: consensus statement of the European Consortium for WM | Leukemia | 2023 | diagnostics | expert opinion | B | DOI |
| E6 | Tam CS, et al. | Zanubrutinib vs Ibrutinib in Symptomatic WM: Final Analysis From the ASPEN Study | J Clin Oncol | 2023 | treatment | RCT | A | DOI |
| E7 | Castillo JJ, et al. | Bendamustine plus rituximab for treatment of WM: patient outcomes and impact of dosing | Am J Hematol | 2023 | treatment | cohort | B | DOI |
| F1 | Gertz MA | WM: 2023 update on diagnosis, risk stratification, and management | Am J Hematol | 2023 | reviews | narrative review | B | DOI |
| D3 | D'Sa S, et al. | Diagnosis and management of WM: BSH guideline | Br J Haematol | 2022 | diagnostics | expert opinion | B | DOI |
| E4 | Dimopoulos MA, et al. | Ibrutinib Plus Rituximab vs Placebo Plus Rituximab for WM: Final iNNOVATE Analysis | J Clin Oncol | 2022 | treatment | RCT | A | DOI |
| C3 | Buske C, et al. | CXCR4 in Waldenström's Macroglobulinemia: chances and challenges | Leukemia | 2021 | genetics | narrative review | B | DOI |
| B1 | Jeong SH, et al. | Incidence, prevalence, mortality, and causes of death in WM: nationwide population-based cohort study | Blood Adv | 2020 | epidemiology | cohort | B | DOI |
| E5 | Tam CS, et al. | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WM: the ASPEN study | Blood | 2020 | treatment | RCT | A | DOI |
| C4 | Castillo JJ, et al. | CXCR4 mutations affect presentation and outcomes in patients with WM: a systematic review | Expert Rev Hematol | 2019 | genetics | systematic review | A | DOI |
| C5 | Castillo JJ, et al. | CXCR4 mutation subtypes impact response and survival outcomes in ibrutinib-treated WM | Br J Haematol | 2019 | genetics | cohort | B | DOI |
| H1 | Van Leersum FS, et al. | Schnitzler's syndrome - a novel hypothesis of a shared pathophysiologic mechanism with WM | Orphanet J Rare Dis | 2019 | pathogenesis | narrative review | B | DOI |
| I1 | Kastritis E, et al. | A revised international prognostic score system for WM | Leukemia | 2019 | epidemiology | cohort | A | DOI |
| C2 | Treon SP, et al. | Insights into the genomic landscape of MYD88 wild-type WM | Blood | 2018 | genetics | cohort | A | DOI |
| E2 | Treon SP, et al. | Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With WM | J Clin Oncol | 2018 | treatment | cohort | A | DOI |
| E3 | Dimopoulos MA, et al. | Phase 3 Trial of Ibrutinib plus Rituximab in WM (iNNOVATE) | N Engl J Med | 2018 | treatment | RCT | A | DOI |
| B2 | Castillo JJ, et al. | Overall survival and competing risks of death in patients with WM | Cancer | 2015 | epidemiology | cohort | B | DOI |
| E1 | Treon SP, et al. | Ibrutinib in Previously Treated Waldenström's Macroglobulinemia | N Engl J Med | 2015 | treatment | cohort | A | DOI |
| E9 | Treon SP | How I treat Waldenström macroglobulinemia | Blood | 2015 | treatment | expert opinion | B | DOI |
| C1 | Hunter ZR, et al. | The genomic landscape of Waldenström macroglobulinemia | Blood | 2014 | genetics | cohort | A | DOI |
| A3 | Varettoni M, et al. | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in WM and related lymphoid neoplasms | Blood | 2013 | genetics | cohort | A | DOI |
| A4 | Poulain S, et al. | MYD88 L265P mutation in Waldenstrom macroglobulinemia | Blood | 2013 | genetics | cohort | A | DOI |
| A2 | Treon SP, et al. | MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia | N Engl J Med | 2012 | genetics | cohort | A | DOI |
| C7 | Kristinsson SY, et al. | What causes WM: genetic or immune-related factors, or a combination? | Clin Lymphoma Myeloma Leuk | 2011 | genetics | narrative review | B | DOI |
| C6 | Royer RH, et al. | Differential characteristics of WM according to patterns of familial aggregation | Blood | 2010 | genetics | cohort | B | DOI |
| A5 | Morel P, et al. | International prognostic scoring system for Waldenström macroglobulinemia | Blood | 2009 | epidemiology | cohort | A | DOI |
| G2 | Stone MJ | WM: hyperviscosity syndrome and cryoglobulinemia | Clin Lymphoma Myeloma | 2009 | clinical | narrative review | B | DOI |
| A1 | Owen RG, et al. | Developing diagnostic criteria in Waldenstrom's macroglobulinemia | Semin Oncol | 2003 | diagnostics | expert opinion | B | DOI |
| D2 | Owen RG, et al. | WM: development of diagnostic criteria and identification of prognostic factors | Am J Clin Pathol | 2001 | diagnostics | cohort | B | DOI |
Pathophysiology Narrative
Waldenström's macroglobulinemia is driven by constitutive activation of the NF-kB survival pathway through the MYD88 L265P gain-of-function mutation, present in >90% of cases (Treon et al., NEJM 2012). This mutation causes spontaneous assembly of the Myddosome complex (MYD88-IRAK4-IRAK1), which in turn activates Bruton's tyrosine kinase (BTK). Both IRAK and BTK converge on NF-kB, promoting B-cell survival, proliferation, and IgM secretion.
The second most frequent molecular event is CXCR4 WHIM-like mutations, found in ~30-40% of patients. These mutations enhance chemokine-driven bone marrow homing via CXCL12/SDF-1, contributing to drug resistance and a more aggressive clinical presentation with higher IgM levels and increased risk of hyperviscosity.
Chromosome 6q deletions occur in ~50% of patients, resulting in loss of TNFAIP3 (A20), a negative regulator of NF-kB, further amplifying the pro-survival signal. Additional genomic events include trisomy 4 (~14%) and 13q14 deletion (~12%).
Mutated MYD88 also transactivates HCK (a SRC family kinase) through PAX5-mediated signaling, which triggers BTK, SYK, and ERK1/2 cascades. The B-cell receptor (BCR) pathway provides additional NF-kB input through SYK-PI3Kd-BTK-PLCg2 signaling.
The IgM paraprotein itself drives many clinical manifestations. Its large pentameric structure causes hyperviscosity at high concentrations. IgM with anti-MAG (myelin-associated glycoprotein) activity causes demyelinating peripheral neuropathy. IgM can also form cryoglobulins, cold agglutinins, or deposit as amyloid fibrils.
Genetic Basis Narrative
The genetic landscape of WM is dominated by the MYD88 L265P somatic mutation, discovered by Treon et al. in 2012 (PMID: 22931316). Using whole-genome sequencing, they identified this mutation in 91% of WM patients. Subsequent studies using allele-specific PCR detected it in up to 100% (Varettoni et al. 2013, PMID: 23355535), establishing it as a molecular hallmark of the disease.
CXCR4 mutations are the second most common event, affecting ~30-40% of patients. These are somatic, WHIM-like mutations (similar to the germline mutations causing WHIM syndrome). Both nonsense (most commonly S338X) and frameshift subtypes occur. CXCR4 mutations are almost exclusively found in MYD88-mutated patients and are associated with higher IgM levels, greater bone marrow involvement, and reduced response to BTK inhibitors.
Approximately 50% of patients harbour chromosome 6q deletions, leading to loss of TNFAIP3 and PRDM1 genes. Other recurrent alterations include trisomy 4, 13q14 deletion, and mutations in ARID1A, TP53, and CD79B.
WM has a significant familial component: ~20% of patients have a first-degree relative with a B-cell disorder. Genome-wide linkage analysis of high-risk families identified susceptibility loci on chromosomes 1q and 4q (OMIM: 610430). Germline variants in DNA repair genes, immune regulators, and telomere-related pathways have been implicated in familial cases.
MYD88 wild-type WM (~5-10% of cases) represents a biologically distinct entity with different genomic landscape (somatic NF-kB-activating mutations in TBL1XR1, PTPN13, MALT1, BCL10), shorter overall survival, and reduced response to ibrutinib.